ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      64,097.90
      0.32%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. ContraFect Corporation (CFRX)

      7. ContraFect Corporation (CFRX) News

      CFRX

      ContraFect (CFRX)

      ContraFect Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CFRX
      DateTimeSourceHeadlineSymbolCompany
      02/14/20242:24PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CFRXContraFect Corporation
      11/15/20234:41PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
      11/08/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
      11/03/20235:08PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CFRXContraFect Corporation
      11/03/202312:16AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CFRXContraFect Corporation
      10/30/20235:24PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
      10/24/20234:06PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
      10/23/20234:05PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CFRXContraFect Corporation
      10/16/20237:30AMGlobeNewswire Inc.ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyNASDAQ:CFRXContraFect Corporation
      09/29/202311:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
      09/25/20238:00AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CFRXContraFect Corporation
      09/19/20238:30AMGlobeNewswire Inc.ContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentNASDAQ:CFRXContraFect Corporation
      09/18/20237:30AMGlobeNewswire Inc.ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370NASDAQ:CFRXContraFect Corporation
      09/14/20234:05PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CFRXContraFect Corporation
      08/28/20238:00AMGlobeNewswire Inc.ContraFect to Present at the World Anti-Microbial Resistance Congress 2023NASDAQ:CFRXContraFect Corporation
      08/18/20235:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
      08/14/20234:18PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CFRXContraFect Corporation
      08/14/20234:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
      08/14/20238:30AMGlobeNewswire Inc.ContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
      07/25/20234:33PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
      06/27/20238:30AMGlobeNewswire Inc.ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionNASDAQ:CFRXContraFect Corporation
      06/27/20238:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
      06/20/20238:59AMGlobeNewswire Inc.ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensNASDAQ:CFRXContraFect Corporation
      06/08/20234:01PMGlobeNewswire Inc.ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023NASDAQ:CFRXContraFect Corporation
      05/16/20236:03AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
      05/15/20234:28PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CFRXContraFect Corporation
      05/15/20238:00AMGlobeNewswire Inc.ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
      05/04/20236:05AMEdgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CFRXContraFect Corporation
      04/28/20234:21PMEdgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:CFRXContraFect Corporation
      04/26/20239:00AMGlobeNewswire Inc.ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeNASDAQ:CFRXContraFect Corporation
       Showing the most relevant articles for your search:NASDAQ:CFRX